Search

Your search keyword '"Cancelliere, A."' showing total 534 results

Search Constraints

Start Over You searched for: Author "Cancelliere, A." Remove constraint Author: "Cancelliere, A." Language undetermined Remove constraint Language: undetermined
534 results on '"Cancelliere, A."'

Search Results

3. Run analysis of potential evapotranspiration and soil moisture for investigating flash droughts in Sicily

4. Modeling extreme meteorological droughts from paleo-climatic reconstructions using a metastatistical framework

5. Deriving hydro-meteorological thresholds for landslide early warning using multi-layer soil moisture information

6. Challenges for flood hazard and risk assessment in Mozambique: the case of Megaruma and Muaguide rivers

7. Assessing the impacts of future climate change scenarios on water systems supplied by karst aquifers

9. Hypertriglyceridemia in young adults with a 22q11.2 microdeletion

10. The butterfly effect: improving brain cone-beam CT image artifacts for stroke assessment using a novel dual-axis trajectory

11. Integrating computational fluid dynamics data into medical image visualization workflows via DICOM

13. Cell Model Network-UK from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy

14. Supplementary Table 1 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy

15. Supplementary Figure 4 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy

16. Supplementary Figure 2 from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

17. Supplementary Figure 2 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy

18. Supplementary Figure 3 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy

19. Supplementary Figure 5 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy

20. Supplementary Figure 1 from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

21. Data from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy

22. Supplementary Figure 3 from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

23. Supplementary Figures 1 - 4 from BRAF V600E Is a Determinant of Sensitivity to Proteasome Inhibitors

24. Supplementary Table 3 from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

25. Supplementary Tables 1 - 3 from BRAF V600E Is a Determinant of Sensitivity to Proteasome Inhibitors

26. Supplementary Figure 4 from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

27. Supplementary Figure 1 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy

28. Supplementary Table 2 from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

29. Supplementary Table 1 from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

30. Data from BRAF V600E Is a Determinant of Sensitivity to Proteasome Inhibitors

31. Data from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

32. Supplementary Table S2 from Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer

33. Data from Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer

34. Supplementary Data from Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer

35. Supplementary Table S1 from Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer

36. Supplementary Figure from Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer

37. Supplementary Table from Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer

38. Supplementary Materials and Methods from Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

39. Supplementary Table S3 from A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin

40. Supplementary Legends and Figures from A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin

41. Supplementary Table S3 from Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer

42. Data from Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

43. Supplementary Figures and Tables from Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

44. Supplementary Table S2 from A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin

45. Supplementary Table S1 from A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin

46. Data from Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer

47. Supplementary Table S4 from A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin

48. Supplementary Figure Legends from Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

49. Data from A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin

50. A Rational Approach to Meshing Cerebral Venous Geometries for High-Fidelity Computational Fluid Dynamics

Catalog

Books, media, physical & digital resources